The Psychedelic Podcast

Bioengineering Psychedelics: Rethinking Sourcing and Scale - Jeffrey E. Gerst, Ph.D.

Mar 30, 2026
Jeffrey E. Gerst, Ph.D., molecular geneticist at the Weizmann Institute who studies RNA and bioengineering. He discusses rethinking psychedelic sourcing, threats from wild harvesting, bioengineering psychedelics in yeast as a scalable alternative, the ethics of ‘natural’ versus engineered supply, and how RNA biology and AI can enable sustainable production.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

Natural Sourcing Won't Meet Global Demand

  • Jeffrey E. Gerst warns natural sourcing can't scale globally for many psychedelics because source species take years to grow and are being depleted.
  • He cites peyote, sassafras for MDMA precursors, and Sonoran desert toads as examples where demand threatens ecosystems and indigenous cultures.
ANECDOTE

Psychedelic Science 2023 Sparked The Bioengineering Focus

  • At Psychedelic Science 2023 Gerst suggested bioengineering psychedelics and met resistance from attendees who asked why change current sourcing.
  • That interaction sparked his realization that scaling would create unsustainable pressure on natural sources like peyote and sassafras.
INSIGHT

Bioengineering As A Sustainable Middle Path

  • Gerst proposes a middle path: bioengineering (genetic engineering) to produce psychedelics in easy-to-grow organisms like yeast to avoid ecological harm and polluting chemistry.
  • He explains many psychedelic pathways require only a few genes (3–5) that have been identified and can be moved into yeast, bacteria, or plants.
Get the Snipd Podcast app to discover more snips from this episode
Get the app